These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30014091)

  • 1. Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.
    Egan AM; Montori VM
    Ann Intern Med; 2018 Jul; 169(2):JC2. PubMed ID: 30014091
    [No Abstract]   [Full Text] [Related]  

  • 2. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
    Gallwitz B
    MMW Fortschr Med; 2010 May; 152(20):43-4. PubMed ID: 20552881
    [No Abstract]   [Full Text] [Related]  

  • 4. SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists.
    Davidson MB
    Ann Intern Med; 2019 Dec; 171(12):JC70. PubMed ID: 31842228
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM; Christensen MB
    Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu O; Azoulay L
    Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do these 3 diabetes agents compare in reducing mortality?
    Martini J; Coe CL; Mounsey A
    J Fam Pract; 2019 Mar; 68(2):99-101. PubMed ID: 30870538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Agents for the Treatment of Type 2 Diabetes.
    Libianto R; Ekinci EI
    Crit Care Clin; 2019 Apr; 35(2):315-328. PubMed ID: 30784612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel indications for GLP-1-analogues and SGLT-2-inhibitors: when should a general practitioner prescribe these agents?].
    Gallwitz B
    MMW Fortschr Med; 2021 Aug; 163(14):57-61. PubMed ID: 34370254
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.
    Fei Y; Tsoi MF; Kumana CR; Cheung TT; Cheung BMY
    Int J Cardiol; 2018 Mar; 254():291-296. PubMed ID: 29277321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004-2014.
    Maltese G; Sinclair AJ
    Diabetes Care; 2024 Apr; 47(4):e32-e33. PubMed ID: 38527117
    [No Abstract]   [Full Text] [Related]  

  • 16. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

  • 17. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH; Udell JA; Filion KB
    Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i.
    Lanzinger S; Schmid SM; Welp R; Zimmermann A; Fasching P; Wagner S; Holl RW
    Diabetes Res Clin Pract; 2018 Dec; 146():162-171. PubMed ID: 30367902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
    Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
    Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.